Ivabradine and Outcomes in Chronic Heart Failure (SHIFT): A Randomised Placebo-Controlled Study
Chronic heart failure affects roughly 2–3% of the population in many industrialised countries.
Ivabradine in Heart Failure the Representativeness of SHIFT (Systolic Heart Failure Treatment with the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients with Chronic Heart Failure
An elevated resting heart rate (HR) is a known risk marker and likely risk factor for adverse outcomes in patients with heart failure (HF).
Efficacy and Safety of Ivabradine in Patients with Chronic Systolic Heart Failure and Diabetes: An Analysis from the SHIFT Trial
Diabetes mellitus and chronic heart failure (HF), both common conditions increasing in prevalence as the general population ages, are significant burdens to public health.
Safety profile and efficacy of Ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial
The cardiomyopathy caused by Chagas disease (ChD) is a major cause of morbidity and mortality in Latin America.
ESC 2019 Day 2 Highlights
ESC Congress focuses on the best and latest science with renowned leaders in cardiovascular medicine. With more than 30,000 delegates – it is the largest such gathering in the world…
ESC 2019 Day 3 Highlights
ESC Congress focuses on the best and latest science with renowned leaders in cardiovascular medicine. With more than 30,000 delegates – it is the largest such gathering in the world…
